Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and tolerability of HSC835 in patients with various hematologic malignancies completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• High-grade Lymphomas
• Large B-cell Lymphoma
• Lymphoblastic Lymphoma
• Lymphocytic Leukemia
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Myelodysplastic Syndrome
• Myelogenous Leukemia

Drugs mentioned

• HSC835

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-12